Bird & Bird advises Genetic Signatures Limited on its successful placement and rights issue raising AUD$16 million

Bird & Bird is pleased to have advised Genetic Signatures Limited, an Australian Securities Exchange listed and Australian-based global molecular diagnostics company, on its successful placement and rights issue to raise approximately AUD$16 million (“Capital Raise”).

The Capital Raise was constituted by an AUD$8 million institutional placement and a fully underwritten AUD$8 million pro-rata non-renounceable rights issue to existing shareholders.

Proceeds from the Capital Raise will be used to fund growth initiatives including US regulatory clearances, US product launches, new instrument development and working capital.

Bird & Bird's team was led by Corporate partner Chris Clarke supported by associate Carl Ritchie.

Chris Clarke comments: “We were delighted to assist Genetic Signatures on this important capital raising, which proves that good businesses can still attract funding notwithstanding difficult capital markets.”  


News & Deals

More News & Deals

News

Bird & Bird and OXYGY announce together with the European Commission and Warren Brandeis the publication of the best practices report 2024 for the European Blockchain Sandbox

Jun 20 2024

Read More

News

Bird & Bird ATMD advised Korea Investment Partners (KIP) on its strategic investment in LiveIn

Jun 19 2024

Read More

Deal

Bird & Bird advised Patria on its acquisition of Nordic Drones

Jun 17 2024

Read More

Deal

Bird & Bird advises Hydrogen Dynamo on the sale of Fjorden Electra to Leica Camera

Jun 14 2024

Read More

News

Bird & Bird and OXYGY announce together with the European Commission 20 use cases selected for second cohort of European Blockchain Sandbox

Jun 13 2024

Read More

Deal

Bird & Bird advises Mews Systems on acquisition of all shares in HS3 Hotelsoftware

Jun 11 2024

Read More